HCRT and obesity due to melanocortin 4 receptor deficiency: Thus, multiple studies have highlighted the therapeutic potential of targeting the orexin system, not only in sleep, cognitive [i.e., Alzheimer's disease (AD)] and metabolic (i.e., obesity) disorders (41–45), but also in ischemic and oxidative stress events (46, 47) and in cancer (48, 49).